In an 84‑year‑old woman who has been using the estradiol transdermal patch (Estradot) for 15 years, when should it be discontinued and what complications can arise from continued use?

When to Stop Estradiol Patch After 15 Years in an 84-Year-Old Woman

Immediate Recommendation: Discontinue Now

The estradiol patch should be discontinued immediately in this 84-year-old woman who has been on therapy for 15 years, as she is far outside the evidence-based treatment window and faces substantially elevated risks of stroke, venous thromboembolism, breast cancer, and dementia that outweigh any remaining symptom benefit. 1, 2

---

Why Discontinuation Is Urgent

Age and Duration Exceed All Safety Guidelines

• Women ≥60 years of age or more than 10 years past menopause have a demonstrably unfavorable risk-benefit profile for hormone therapy, with oral estrogen-containing formulations receiving a Class III, Level A recommendation against use due to excess stroke risk 1, 2

• Although transdermal estradiol avoids the hepatic first-pass metabolism that increases stroke risk with oral formulations, no guideline supports continuation beyond age 60–65 in the absence of compelling indications, and this patient is 84 years old with 15 years of exposure 2, 3

• The FDA explicitly mandates that estrogen therapy be prescribed at the lowest effective dose for the shortest duration consistent with treatment goals, and 15 years of continuous use in an octogenarian violates this core principle 4, 2

Vasomotor Symptoms Typically Resolve Within 2–5 Years

• The median duration of bothersome menopausal symptoms is 2–5 years after natural menopause, and this patient is now decades past that window 2

• At age 84, any residual vasomotor symptoms are exceedingly rare and do not justify the cumulative risks of prolonged hormone exposure 2

---

Specific Complications of Continued Use at Age 84

1. Stroke Risk

• For every 10,000 women aged ≥60 years taking combined estrogen-progestogen therapy for one year, there are 8 additional strokes 1, 2

• Although transdermal estradiol does not increase stroke risk in women <60 years or within 10 years of menopause, the protective window closes after age 60, and stroke risk rises with advancing age regardless of formulation 1, 5

• The absolute stroke risk in an 84-year-old woman on hormone therapy is substantially higher than the 8 per 10,000 figure derived from younger cohorts 1

2. Venous Thromboembolism (VTE)

• Combined estrogen-progestogen therapy adds 8 pulmonary emboli per 10,000 women-years in the 60+ age group 2

• While transdermal estradiol does not increase VTE risk in healthy younger women, age itself is a major VTE risk factor, and the safety data for transdermal formulations come from women <80 years 6, 7

• At 84 years, baseline VTE risk is elevated due to age-related immobility, comorbidities, and vascular changes, making any estrogen exposure riskier 6

3. Breast Cancer

• Breast cancer risk with combined estrogen-progestogen therapy becomes statistically significant after 4–5 years of use, with 8 additional invasive breast cancers per 10,000 women-years 4, 2

• After 15 years of continuous exposure, this patient's cumulative breast cancer risk is substantially elevated, with a relative risk of 1.24–1.26 for combined therapy 2, 4

• Invasive breast cancers diagnosed in women on combined hormone therapy are larger, more likely node-positive, and diagnosed at more advanced stages than in non-users 4

• Even if this patient is on estrogen-alone therapy (patch without progestogen), the risk increases with duration beyond 10 years, and the protective effect seen in shorter-term estrogen-alone use does not apply to 15-year exposures 8

4. Dementia

• The Women's Health Initiative Memory Study (WHIMS) found that women aged ≥65 years on combined estrogen-progestogen therapy had a 2.05-fold increased risk of probable dementia (95% CI 1.21–3.48) 4

• The absolute risk was 45 versus 22 cases per 10,000 women-years, with an absolute excess risk of 23 cases per 10,000 women-years for hormone therapy versus placebo 4

• This patient, at age 84, is at the highest risk for dementia, and continued hormone exposure may accelerate cognitive decline 4

5. Endometrial Cancer (If Uterus Intact)

• If this patient has an intact uterus and has been on unopposed estrogen (patch without progestogen), her endometrial cancer risk is 10- to 30-fold elevated after 5+ years of use, with a relative risk of 2.3–9.5 4, 2

• The risk persists for 8–15 years after discontinuation, meaning she already faces long-term endometrial cancer risk even after stopping 4

• If she has been on combined estrogen-progestogen therapy, endometrial cancer risk is reduced by ~90%, but this does not mitigate the other cumulative risks 2

6. Gallbladder Disease

• Estrogen therapy increases the risk of gallbladder disease requiring surgery by 2- to 4-fold in postmenopausal women 4

• At age 84, surgical risk is higher due to age-related comorbidities, making gallbladder complications more dangerous 4

7. Ovarian Cancer

• A meta-analysis of 52 epidemiologic studies found that hormone therapy for menopausal symptoms increased ovarian cancer risk, with a relative risk of 1.41 (95% CI 1.32–1.50) for current users 4

• The risk was elevated for both estrogen-alone and combined estrogen-progestogen products, and duration of use beyond 5 years further increased risk 4

---

How to Discontinue Safely

Abrupt Discontinuation Is Preferred

• Stop the patch immediately without tapering, as there is no evidence that gradual dose reduction prevents symptom recurrence or improves outcomes 2

• Tapering is a common practice but lacks evidence-based support and only prolongs exposure to cumulative risks 2

Manage Potential Withdrawal Symptoms

• At age 84 and 15 years post-menopause, vasomotor symptom recurrence is unlikely, as the natural history of hot flashes is resolution within 2–5 years 2

• If mild hot flashes do recur, non-hormonal alternatives are safer:

  • Selective serotonin reuptake inhibitors (SSRIs) reduce vasomotor symptoms without cardiovascular risk 1, 2
  • Gabapentin is effective for hot flashes in women with contraindications to hormone therapy 2
  • Cognitive-behavioral therapy or clinical hypnosis can reduce hot flashes 2

Address Genitourinary Symptoms Separately

• If the patient has vaginal dryness, dyspareunia, or urinary urgency, these can be managed with low-dose vaginal estrogen preparations (rings, suppositories, or creams) 2

• Vaginal estrogen delivers high local concentrations with minimal systemic absorption, avoiding the stroke, VTE, and breast cancer risks of systemic therapy 2

• Vaginal estrogen does not require concurrent progestogen even in women with an intact uterus, as systemic absorption is negligible 2

Bone Health After Discontinuation

• Stopping hormone therapy will result in accelerated bone loss (2% annually in the first 5 years), but at age 84, the patient is already at high fracture risk regardless of hormone status 2, 8

• Bisphosphonates, denosumab, or selective estrogen receptor modulators (SERMs) are safer alternatives for osteoporosis prevention in this age group 2

• Ensure adequate calcium (1,000–1,300 mg/day) and vitamin D (800–1,000 IU/day) supplementation 2

• Encourage weight-bearing exercise to maintain bone density 2

---

Critical Pitfalls to Avoid

Do Not Continue Therapy "Because She's Been on It So Long"

• Sunk-cost fallacy: The fact that she has been on the patch for 15 years does not justify continued exposure; it actually increases her cumulative risk and makes discontinuation more urgent 2, 4

• The "window of opportunity" for cardiovascular protection closes at age 60 or 10 years post-menopause, and this patient is 24 years past that window 1, 2

Do Not Assume Transdermal Estradiol Is "Safe" at Any Age

• While transdermal estradiol avoids the hepatic first-pass effects that increase stroke and VTE risk with oral estrogen, it does not eliminate all risks, and the safety data come from women <80 years 3, 5, 6

• At age 84, baseline cardiovascular and cancer risks are so high that even modest relative risk increases from hormone therapy translate into substantial absolute harm 1, 2

Do Not Initiate a "Taper" to Avoid Withdrawal Symptoms

• There is no evidence that tapering prevents symptom recurrence or improves outcomes, and it only prolongs exposure to cumulative risks 2

• At 84 years and 15 years post-menopause, vasomotor symptom recurrence is exceedingly rare, and any symptoms that do occur can be managed with non-hormonal alternatives 2

Do Not Ignore the U.S. Preventive Services Task Force (USPSTF) Grade D Recommendation

• The USPSTF assigns a Grade D recommendation (recommends against) for using hormone therapy solely for chronic disease prevention in postmenopausal women, as the harms outweigh benefits 1, 2

• This patient is far beyond the symptom-management indication and is now in the "chronic disease prevention" category, where hormone therapy is explicitly contraindicated 1, 2

---

Summary Algorithm for This Patient

1. Confirm the indication for initial therapy: Was the patch started for vasomotor symptoms, surgical menopause, or premature ovarian insufficiency? (At age 84 with 15 years of use, the original indication is now irrelevant.) 2

2. Assess current symptom burden: Does she have bothersome hot flashes, night sweats, or genitourinary symptoms? (Unlikely at age 84 and 15 years post-menopause.) 2

3. Screen for absolute contraindications that have developed: History of stroke, VTE, breast cancer, coronary artery disease, or active liver disease? (If any are present, discontinuation is even more urgent.) 2, 4

4. Discontinue the patch immediately without tapering. 2

5. Counsel on non-hormonal alternatives for any residual symptoms (SSRIs, gabapentin, cognitive-behavioral therapy). 1, 2

6. Prescribe low-dose vaginal estrogen if genitourinary symptoms are present (rings, suppositories, or creams). 2

7. Optimize bone health with calcium, vitamin D, weight-bearing exercise, and consider bisphosphonates or denosumab if bone density is low. 2, 8

8. Schedule follow-up in 3 months to assess for symptom recurrence and reinforce the decision to discontinue. 2

---

Final Word

This 84-year-old woman should stop the estradiol patch immediately. She is far outside the evidence-based treatment window, and her cumulative risks of stroke, VTE, breast cancer, dementia, and other complications vastly outweigh any theoretical benefit. The patch should have been discontinued at age 60–65, and continuing it to age 84 represents a significant deviation from guideline-based care. Discontinuation is urgent, and any residual symptoms can be managed with safer non-hormonal alternatives or low-dose vaginal estrogen. 1, 2, 4